- Report
- July 2023
- 808 Pages
Global
From €2211EUR$2,500USD£1,909GBP
- Report
- June 2023
- 33 Pages
Global
From €1725EUR$1,950USD£1,489GBP
- Report
- July 2024
- 26 Pages
Global
From €1725EUR$1,950USD£1,489GBP
- Report
- March 2024
- 44 Pages
Global
From €8839EUR$9,995USD£7,632GBP
- Report
- March 2025
- 82 Pages
From €2609EUR$2,950USD£2,252GBP
- Report
- October 2023
- 689 Pages
Global
From €8839EUR$9,995USD£7,632GBP
- Report
- February 2024
- 88 Pages
Global
From €3500EUR$4,240USD£3,128GBP
- Report
- January 2024
- 98 Pages
Global
From €3500EUR$4,240USD£3,128GBP
- Report
- July 2024
- 154 Pages
Global
From €3759EUR$4,250USD£3,245GBP
- Report
- January 2024
- 100 Pages
Global
From €3500EUR$4,240USD£3,128GBP
- Report
- December 2023
- 132 Pages
Global
From €840EUR$950USD£725GBP
- Book
- May 2021
- 224 Pages
- Book
- March 2014
- 144 Pages
- Book
- September 2013
- 152 Pages

Age-related Macular Degeneration (AMD) is a degenerative eye condition that affects the macula, the part of the eye responsible for central vision. It is the leading cause of vision loss in people over the age of 50. AMD is a major concern for the optical industry, as it can lead to severe vision impairment and blindness.
Optical companies are developing treatments and technologies to help diagnose and manage AMD. These include optical coherence tomography (OCT) imaging, which can detect early signs of AMD, and anti-VEGF drugs, which can slow the progression of the disease. Additionally, companies are developing new lenses and other optical devices to help improve vision in those with AMD.
Companies in the AMD market include Novartis, Regeneron, Allergan, Genentech, and Roche. Show Less Read more